Sorrento Therapeutics, Inc. · OTC:SRNE
Sorrento Therapeutics — Investor Presentation (January 2016)
52 slides from Sorrento Therapeutics's investor presentation, January 2016

Slide 1: Corporate Presentation
Therapeutics Corporate Presentation Henry Ji, PhD - President and CEO © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED.

Slide 2: Disclaimer
Disclaimer NASDAQ: SRNE Certain statements contained in this presentation or in other documents of In presenting this material or responding to inquiries in connection with a Sorrento Therapeutics, Inc. (the “Company”), along with certain statements presentation, management may refer to results, pro

Slide 3: G-MAB Library
G-MAB Library Highly Successful Screening Hit Rate Fully Human Antibodies (100+ targets screened) Proprietary Technology Very High Diversity RNA amplification used for library generation 2.1 x 1016 Distinct Antibodies Difficult Targets High Value Oncology Targets Most Difficult Targets: Small Peptid

Slide 4: (C) 2015 Sorrento Therapeutics, Inc. All Rights Reserved.
(C) 2015 Sorrento Therapeutics, Inc. All Rights Reserved.

Slide 5: Drug Targets: Location
Drug Targets: Location Location Secreted Targets Intracellular Targets Extra-Cellular Location Membrane Targets © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED.

Slide 6: Antibodies against Secreted Targets
Antibodies against Secreted Targets TNF-α IgE VL VH CH1 CL CH2 CH3 CH4 © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED.

Slide 7: Antibodies Against Membrane Targets
Antibodies Against Membrane Targets PD-L1 EGFR CD-25 © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED.

Slide 8: Antibodies Against Intracellular Targets
Antibodies Against Intracellular Targets KRAS STAT3 © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED.

Slide 9: Sorrento BioSimilar mAb and BioBetter mAbs
Sorrento BioSimilar mAb Sorrento BioBetter mAbs IgE TNF-α VL VH CH1 CL CH2 CH3 CH4 Infliximab STI-002 Omalizumab STI-004 CD25 EGFR Cetuximab Basiliximab STI-001 STI-003 © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED.

Slide 10: Bispecific Antibodies
Bispecific Antibodies c-MET PD-L 1 - L1 PD EGFR © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED.

Slide 11: Antibody Drug Conjugates (ADCs)
Antibody Drug Conjugates (ADCs) c-MET HER2 © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED.

Slide 12: Chimeric Antigen Receptors (CARs)
Chimeric Antigen Receptors (CARs) CAR-T CAR.NK © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED.

Slide 13: Positioning
Positioning T-cells NK Natural Killer cells CAR-T CAR.NK © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED.

Slide 14: Sorrento Immunotherapy Platform
Sorrento Immunotherapy Platform ADCs Antibody Drug Conjugates Proprietary Toxins Intracellular c-MET Conjugation Chemistries Targets Adoptive Immunotherapy PD-L1 Bispecific Abs Secreted Chemical BsAb (CBAs) Targets IgG-based Proprietary Biochemistry CAR.NK CAR-T © 2015, Sorrento Therapeutics, Inc. A

Slide 15: Pipeline
Pipeline Code Target Preclinical Phase I Phase II Phase III STI-001 EGFR STI-002 TNF-α STI-003 CD25 mAbs STI-004 IgE STI-1014 PD-L1 STI-1110 PD1 CAR-T CEA CAR-T PSMA CAR-T CAR-T GD3 CAR-T IL13R CAR-T c-KIT CAR.TNK PD-L1 CAR.TNK CAR.TNK ROR1 Resiniferatoxin RTX TRPV1 ** Partnered with NantKwest * Com

Slide 16: Sorrento LA Cell
Con cor tis n o BiSpecific ADC m u Abs s m I Oncology CAR tibody Therapeu .TNK An tics LA Cell CAR-pNK Cellular Therapies Sorrento Therapeutics Intracellular mAbs TNK t i c s Th A ntib o d y Th e ra p eu R-T er CA ap ut e ic s Bio Sim t t e r ilar / BioBe mAbs Sorrento Biologics © 2015, Sorrento The

Slide 17: Sorrento Biologics
Sorrento Biologics (C) 2015 Sorrento Therapeutics, Inc. All Rights Reserved.

Slide 18: Significant Near-Term Commercial Opportunities
Significant Near-Term Commercial Opportunities o Worldwide market for biosimilar products with Product Generic Target Brand 2014 Global Sales (US$) Originators’ global sales of STI-001 Cetuximab EGFR Erbitux $1.9B $100 B+ in 2014 o Four leading biosimilar / STI-002 Infliximab TNFα Remicade $9B biobe

Slide 19: STI-001 Biosimilar/Biobetter mAb to Cetuximab
STI-001 Biosimilar/Biobetter mAb to Cetuximab (C) 2015 Sorrento Therapeutics, Inc. All Rights Reserved.

Slide 20: Cetuximab: STI-001 vs Erbitux
Cetuximab: STI-001 vs Erbitux STI-001 PBS buffer Modified (C) 2015 Sorrento Therapeutics, Inc. All Rights Reserved.

Slide 21: STI-001: Comparable to Erbitux in vitro and in vivo
STI-001: Comparable to Erbitux in vitro and in vivo STI-001 demonstrates in vivo efficacy in animal tumor models (C) 2015 Sorrento Therapeutics, Inc. All Rights Reserved.

Slide 22: STI-001: Demonstrated Clinical Efficacy
STI-001: Demonstrated Clinical Efficacy STI-001 Erbitux Erbitux Ph3 STI-001 trial Ph2/3 trial Cetuximab + STI-001 + irinotecan irinotecan (n=218), (n=337) Overall 22.9 32.9 response [17.5-29.1) [27.9-38.2] Time (days) rate Disease 55.5 80.1 Time to progression (TTP) Progression Free Survival (PFS) c

Slide 23: STI-001: Favorable Carbohydrate Structure With Fewer Side Effects
STI-001: Favorable Carbohydrate Structure With Fewer Side Effects 0.64 0.02 0.05 6.93 • MAbs. 2013 Sep-Oct;5(5):699-710 • N Engl J Med. 2008 Mar 13;358(11):1109-17 • MAbs. 2011;3:505–12 (C) 2015 Sorrento Therapeutics, Inc. All Rights Reserved.

Slide 24: STI-001: Improved Safety Compared to Erbitux
STI-001: Improved Safety Compared to Erbitux Erbitux STI-001 AE’s Cetuximab Cetuximab STI-001+ Irinotecan Grades 3 & + irinotecan monotherapy irinotecan monotherapy (n=218) (n=111) (n=337) (n=164) 4 Any 138 (65.1) 50 (43.5) 180 (54.2) 57 (38.9) Anemia 10 (4.7) 3 (2.6) 3 (0.9) 3 (1.8) Neutropenia 20

Slide 25: STI-002 BioSimilar / BioBetter mAb to Infliximab
STI-002 BioSimilar / BioBetter mAb to Infliximab (C) 2015 Sorrento Therapeutics, Inc. All Rights Reserved.

Slide 26: Infliximab: STI-002 vs Remicade
Infliximab: STI-002 vs Remicade STI-002 (C) 2015 Sorrento Therapeutics, Inc. All Rights Reserved.

Slide 27: STI-002: Comparable Structure and Function to Remicade
STI-002: Comparable Structure and Function to Remicade 6000 3 Remicade 4000 Red: STI-002 STI-002 Green: Remicade OD (450 nm) 2 2000 Mol. Ellip. 1 0 -2000 0 -14 -13 -12 -11 -10 -9 -8 logM -4000 195 220 240 260 STI-002 Remicade Wavelength [nm] EC50 4.025e-011 3.316e-011 T N F a n e u t r a liz a t io

Slide 28: STI-002 Demonstrated Clinical Efficacy in RA Patients
STI-002 Demonstrated Clinical Efficacy in RA Patients 2W 6W 10W 14W 18W Group A (n=330) Infliximab +MTX Follow up Group C (n=110) Infliximab +MTX Placebo+MTX Follow up Group B (n=110) Placebo+MTX Follow up 0w 2w 6w 14w 18w (C) 2015 Sorrento Therapeutics, Inc. All Rights Reserved.

Slide 29: STI-002 Showed Reduced Immunogenic Reactions
STI-002 Showed Reduced Immunogenic Reactions Remicade Phase I (Healthy volunteers and RA patients) Single dose (vd) Multi-dose (vd (Healthy volunteers) 0,2,6,10,14w)(RA patients) Dosage 1 3 mg/kg 10 3 mg/kg mg/kg mg/kg STI-001 ADA 2/9 0/9 0/9 1/10 incidence Phase III (RA patients) Multi-dose (vd 0,2

Slide 30: STI-003 Biosimilar/Biobetter mAb to Basiliximab
STI-003 Biosimilar/Biobetter mAb to Basiliximab (C) 2015 Sorrento Therapeutics, Inc. All Rights Reserved.

Slide 31: Basiliximab: STI-003 vs Simulect
Basiliximab: STI-003 vs Simulect STI-003 (C) 2015 Sorrento Therapeutics, Inc. All Rights Reserved.

Slide 32: STI-004 Biosimilar mAb to Omalizumab
STI-004 Biosimilar mAb to Omalizumab (C) 2015 Sorrento Therapeutics, Inc. All Rights Reserved.

Slide 33: Omalizumab: STI-004 vs Xolair
Omalizumab: STI-004 vs Xolair STI-004 High sucrose Modified (C) 2015 Sorrento Therapeutics, Inc. All Rights Reserved.

Slide 34: LA Cell, Inc.
LA Cell, Inc. Cell-internalizing Antibody Technology for Drugging of Undruggable Targets © 2015 LA Cell, Inc. All Rights Reserved.

Slide 35: Cell-internalizing Antibodies Penetrate into Live Cells and Recognize Their Targets
Cell-internalizing Antibodies Penetrate into Live Cells and Recognize Their Targets 1. Modified anti-MYC tag antibody 2. Cells were fixed and then stained 3. Yellow signal (overlay of green & stains live CHO cells transfected with unmodified anti-FLAG tag red fluorescent signals) shows with MYC- and

Slide 36: Anti-tumor Effect of Modified anti-KRAS G12D mAbs in PANC-1 Tumors
Anti-tumor Effect of Modified anti-KRAS G12D mAbs in PANC-1 Tumors • KRAS mutations, especially KRAS G12D, common in pancreatic and lung cancers • No drugs yet that directly inhibit KRAS oncogenic activities • Modified KRAS G12D antibodies effectively inhibit KRAS oncogenic activity in vivo, leading

Slide 37: Targeting FoxP3 by the Cell-internalizing Antibody Reduces Tumor-associated Tregs
Targeting FoxP3 by the Cell-internalizing Antibody Reduces Tumor-associated Tregs and Tumor Growth • Regulatory T cells (Tregs) suppress anti- tumor immune responses • Foxp3 is essential for Tregs maintenance • However, Foxp3 is deemed undruggable • Modified Foxp3 antibodies inhibit Foxp3, reducing

Slide 38: Anti-tumor Efficacy of Modified Antibodies Targeting HPV16/18 E6 Oncoprotein
Anti-tumor Efficacy of Modified Antibodies Targeting HPV16/18 E6 Oncoprotein in Cervical Cancer • Human papillomavirus (HPV) E6 and E7 proteins represent promising targets for therapy of cervical cancer and head-and- neck cancer • Currently no effective antiviral agent available for anti-cancer ther

Slide 39: The Cell-Penetrating Antibody Delivery Platform
The Cell-Penetrating Antibody Delivery Platform • Conjugation of antibodies with specifically-modified short oligonucleotides enables efficient cellular internalization, intracellular target recognition and inhibition • Various conjugation chemistries, including both covalent and non-covalent attach

Slide 40: Harnessing Adaptive and Innate Immunity
Harnessing T Cell Adaptive and Innate NK Immunity © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED.

Slide 41: Positioning
Positioning T-cells NK Natural Killer cells CAR-T CAR.NK © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED.

Slide 42: G-MAB CAR-T and CAR.NK
G-MAB Library Clinical stage programs for solid tumors Chimeric Antigen Receptor (CAR)-based Immunotherapies harnessing: CAR-T and CAR.NK • T-cell immunity with CAR-T therapy (autologous) • Natural Killer cell immunity with CAR.NK therapy (off-the-shelf ) Granzyme Multi-pronged strategy to increase

Slide 43: Therapeutic Platform
Therapeutic Platform CAR-T Programs G-MAB CAR.NK Technology Acquisition NK CAR-T Fully human antibody library © 2015, TNK Therapeutics, Inc. ALL RIGHTS RESERVED.

Slide 44: Autologous CAR-T Manufacturing
Autologous CAR-T Manufacturing Leukapheresis PBMC collection T-cell activation (Peripheral Blood Mononuclear Cells) (CD3 antibody + cytokines) CAR-T Infusion CAR-T CAR-T Cell Expansion Viral Transduction Drug Product © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED.

Slide 45: CEA CAR-T in Metastatic Liver Cancer Patients
CEA CAR-T in Metastatic Liver Cancer Patients 100% #4 #8 ACTIVITY IN HEAVILY 80% PRE-TREATED GROUP #6 Survival 60% P#5 alive >130 weeks #7 Average of 2.5 lines prior chemotherapy 40% #1 Average size of largest tumor = 8.4 cm 20% #5 4 patients with > 10 liver tumors 0% 0 20 40 60 80 100 120 Weeks Sou

Slide 46: IL13 CAR-T: Inhibition of Tumor Growth of Xenograft Glioma
IL13 CAR-T: Inhibition of Tumor Growth of Xenograft Glioma 100% 80% Tumor + Survival 60% IL13 CAR-T cells (n=11) 40% Tumor + 20% Tumor only Untransduced T Cells (n=10) (n=4) 0% 0 20 40 60 80 100 120 Days Source: Kong et al. Clin Cancer Res. 18(21):5949-60, 2012 © 2015, Sorrento Therapeutics, Inc. AL

Slide 47: CAR.TNK cGMP Manufacturing Process
CAR.TNK cGMP Manufacturing Process Off-the-shelf Drug Product BioReactor Electroporation cell expansion or NK92 CAR.TNK Viral Transduction CAR.TNK CAR.TNK cGMP CAR.TNK Manufacturing CAR © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED.

Slide 48: HER2.TNK in Glioma Model
HER2.TNK in Glioma Model Survival 100 (%) p<0.01 80 272 Days 60 40 20 Medium NK92 CAR.TNK Days 80 120 160 200 240 280 Source: Schönfeld et al., Mol Ther. 23(2):330-8, 2015 © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED.

Slide 49: Diagnostic Platform
Diagnostic Platform CTC G-MAB (Circulating Tumor Cells) CTC Panel for Cancer Patients PD-L1 CEA GD3 ROR1 Exclusive License for Fully human CD123 cell-based therapies antibody library © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED.

Slide 50: Precision Medicine Profiling
Precision Medicine Diagnostic Patients Profiling Treatment & Maintenance Hospital CAR Selection CARs CAR-T / CAR.NK © 2015, Sorrento Therapeutics, Inc. ALL RIGHTS RESERVED.

Slide 51: Sorrento LA Cell
Con cor tis n o BiSpecific ADC m u Abs s m I Oncology CAR tibody Therapeu .TNK An tics LA Cell CAR-pNK Cellular Therapies Sorrento Therapeutics Intracellular mAbs TNK t i c s Th A ntib o d y Th e ra p eu R-T er CA ap ut e ic s Bio Sim t t e r ilar / BioBe mAbs Sorrento Biologics

Slide 52: Contact
Therapeutics Contact Henry Ji, PhD - President and CEO hji@sorrentotherapeutics.com (858) 668-6923
Source: Internet Archive copy of sorrentotherapeutics.com
More decks from Sorrento Therapeutics, Inc.
Presentation (August 2023)9 slides · Aug 1, 2023
SPAC Merger (March 2022)21 slides · Mar 18, 2022
Technical Presentation (January 2022)13 slides · Jan 21, 2022
SPAC Merger (December 2021)57 slides · Dec 13, 2021
Technical Presentation (November 2021)9 slides · Nov 29, 2021
Investor Presentation (September 2021)37 slides · Sep 13, 2021